Pavmed Inc. · NASDAQ:PAVM
Pavmed — Investor Presentation (October 2017)
27 slides from Pavmed's investor presentation, Oct 10, 2017
Slide 1: PAVmed: Innovating at the Speed of Life
x PAVmed INNOVATING AT THE SPEED OF LIFE™ NASDAQ: PAVM LISHAN AKLOG MD, CHA/RMAN & CEO DENNIS MCGRATH, Executive VP &CFO SK PAVmed
Slide 2: Disclaimers
Disclaimers 5 This presentation contains certain forward-looking statements that involve risks and uncertainties. * Actual results and events may differ significantly from results and events discussed in forward-looking statements. = Factors that might cause or contribute to such differences include
Slide 3: Highly Differentiated, Multi-Product Medical Device Company
x PAVmed INNOVATING AT THE SPEED OF LIFE HIGHLY DIFFERENTIATED, MULTI-PRODUCT MEDICAL DEVICE COMPANY %& Nasdaq-listed: PAVM % High-margin, high-impact single-use interventional or acute care products %& Broad spectrum of clinical conditions and specialty call points
Slide 4: Strong Track Record, Speed to Market, Two Near-term Milestones
Strong Track Record Speed to Market Two Near-term of Innovation and - = Milestones A Capital Efficiency Value Creation Multiple Pathways to Yeiel BGcierse te Market over $3B Commercialization
Slide 5: Key Recent Developments
Key Recent Developments ¥% Balance sheet strengthened = $8.5 million in raised in 2017 from seasoned healthcare investors = Adequate capital into Q2 2018 through key regulatory milestones Steady progress towards lead product milestones = PortlO FDA de novo re-submission this quarter = CarpX FDA 510(
Slide 6: Capital Structure
Capital Structure PAVmed, Inc (Nasdaq:PAVM, PAVMW) Exercise/ Common Stock Insider Conversion Price Equivalents Outstanding Ownership (Weighted Avg.) (Treasury) Common Stock 13,331,211 64% 13,331,211 Preferred Stock 560,822 0% $4.80 649,034 Warrants 13,840,533 61% $4.11 4,133,265 Options 1,974,924 $5
Slide 7: PAVmed's Founders
PAVmed’s Founders LISHAN Harvarn AX AKLOG Minn om @3 PAVILION MD : Sinai aii CHAIRMAN So] ao Se Dienity Health Pavilion & CEO Oe eiateeetn Wy University of MIGHIAEE wee ASCENT” Qi PAVILION GLENNON STORZ MOLDINGS GROUP a sever Cf ymedtronic Pavilion HAIRMAN —— edie innovations MEDSYSTEMS acceHlent BR
Slide 8: PAVmed's History
PAVmed’s History PAVILION” ~ Vee AL ied PAVmed 2008-2013 NASDAQ IPO z PAVMED MPLETED FIRST FDA 510K A FOUNDED SUBMISSION Ss XS cocoon’ | OES “as COM ociel 00M a Bis re oth 98 5 eee] a on 5 oy INITIAL PIPELINE OF SIXTH PRODUCT LICENSED as ae peo EIVEINNOVETIONS FROM ACADEMIC CONSORTIUM 2a etoascore @
Slide 9: Business Model
Business Model LTI-PRODU PIPELINE RISK MITIGATION COMMERCIA + Non-binary success OPPORTUNITY ECONOMIES OF SCALE ATTRACTIVE MARKET 'Y BUSINESS + Unmet clinical need PROCESSES CORPORATE FLEXIBILITY E aemiorseninee ~Regulalonpaliway ‘CAPITAL EFFICIENCY & allocation HIGH-MARGIN PRODUCT SPEED TO MARKET +
Slide 10: Lead Products
Lead Products MARKET REGULATORY peepee | OPPORTUNITY PATH CARPX Percutaneous Device to treat >$1B 510(k) Carpal Tunnel Syndrome PORTIO /mplantable Intraosseous >$750M de novo Vascular Access Device DISAPPEAR Antibiotic-Eluting ~$300M 510(k) Resorbable Ear Tubes “PAVmed hae not yet received clearance
Slide 11: Multiple Pathways to Commercialization
Multiple Pathways to Commercialization Tailored to Maximize Value Creation TARGETED INITIAL COMMERCIALIZATION - Key Opinion Leaders + Independent Distributors CORPORATE CORPORATE FULL SELF ACQUIRER PARTNER COMMERCIALIZATION -Asset sale to strategic + Sales & distribution + Hybrid sales channel + Non
Slide 12: CarpX
= CarpX Percutaneous Device to Treat Carpal Tunne/ Syndrome
Slide 13: Carpal Tunnel Syndrome
Carpal Tunnel Syndrome CLINICAL OVERVIEW Incidence = Over 600,000 U.S. procedures annually = Up to 1.5 million with symptoms who “suffer in silence” x Mechanism = Inflammation and scarring of transverse carpal ligament = Entrapment of the median nerve = hand pain, numbness and weakness ere) PAVmed
Slide 14: Carpal Tunnel Syndrome: Market Opportunity
Carpal Tunnel Syndrome MARKET OPPORTUNITY 3 600,000 current surgeries x $1,500 minimum ASP = ~$1 Billion ¢ Additional 1.5M “silent sufferers” who choose to defer surgery UNMET CLINICAL NEED — CURRENT LIMITATIONS TRADITIONAL CARPAL TUNNEL ENDOSCOPIC SURGERY SURGERY IS INVASIVE IS LESS EFFECTIVE +Up t
Slide 15: CarpX: The PAVmed Solution
CarpX — The PAVmed Solution PERCUTANEOUS DEVICE TO TREAT CARPAL TUNNEL SYNDROME Components = Balloon catheter = Integrated bipolar RF cutting electrodes = Control handle Key Features = Single-use device = Connects to standard electrosurgical generator = Balloon provides anatomic separation = Pushes
Slide 16: CarpX in Action
CarpX in Action x y — & Balloon inflated (sideview) Transverse carpal ligament cut PAVmed
Slide 17: CarpX: The PAVmed Solution
CarpX — The PAVmed Solution LESS INVASIVE MORE COST EFFECTIVE % Truly percutaneous 38 Shift from OR to interventional la %¢ No surgical incision or dissection ’¢ Shorten procedural times % Less pain, scarring and recovery % Shorten recovery time and return time to work FEWER COMPLICATIONS EXPANDED M
Slide 18: CarpX: Current Status
CarpX — Current Status % FDA Submission Imminent = Testing completed = 510(k) application being drafted = Smith & Nephew carpal release system as predicate Commercialization Strategy established = Initial launch using independent distributors = Hand Surgery/Interventional Radiology Key Opinion Leade
Slide 19: PortIO
PortlO /mplantable Intraosseous Vascular Access Devices SK PAVmed
Slide 20: Vascular Access Devices
Vascular Access Devices Used to deliver medications, fluids, nutrition and other substances ER INPATIENT <24 Hours <7-10 days <6 weeks <1 year Intraosseous Central Venous Device Catheter (CVC) Tunneled Central Venous Catheter Peripherally Inserted Central Implantable Port Catheter (PICC) (Port-a-Cat
Slide 21: Vascular Access Devices: Unmet Clinical Need
Vascular Access Devices UNMET CLINICAL NEED — CURRENT DEVICE LIMITATIONS Limitations driven by intravascular component OCCLUSION | INFECTION + Up to 35% + Up to 10% + Clot-busting medications or * 50% life-threatening a repeat procedure bloodstream infections POOR VEINS RESOURCE UTILIZATION + >10% o
Slide 22: Intraosseous Vascular Access
Intraosseous Vascular Access Infusion directly into the Bone Marrow Cavity & Decades of experience = Trauma, esp. military = Pediatric emergencies peers = Bioequivalent to Device intravenous route
Slide 23: PortIO: Implantable Intraosseous Port
PortlO — Implantable Intraosseous Port ¥ Components = Titanium body = Internal conical needle guide Implantable * Hollow titanium bone screw gene Huber Access Needle = Silicone septum % Implanted into bone = Tip positioned in bone marrow = No Intravascular Component ee Hollow — Titanium Silicone Fun
Slide 24: PortIO: Market Opportunity and Regulatory Strategy
PortlO — Implantable Intraosseous Port Market opportunity and regulatory strategy function of implant duration Duration Duration Duration <24 Hours <7-10 days <6 weeks <1 year Market Size Market Size Market Size ~$150M ~$200M (Poor vein pts) ~$500M Advantages Advantages Advantages + Near limitless a
Slide 25: PortIO: Current Status
PortlO — Current Status & FDA de novo application in process = 7-day inpatient indication = Majority of testing completed, 7-day animal study to be initiated = Pre-submission meeting package submission imminent % Commercialization Strategy established = Initial launch using independent distributors
Slide 26: Growth Strategy
Growth Strategy ¥% Raise permanent capital % Advance products to commercialization = PortlO — Q4-2017 FDA de novo submission = CarpX — FDA 510(k) submission imminent = DisappEAR — Q3 2018 FDA submission = Accelerate R&D products into commercialization channel ¥ Explore M&A acquisition targets = Smal
Slide 27: PAVmed: Leadership, Business Model, Product Pipeline
*_ PAVmed PROVEN PROVEN EXPANDING LEADERSHIP BUSINESS PRODUCT TEAM MODEL PIPELINE Strong Track Record Speed to Market Two Near-term of Innovation and Milestones A Capital Efficiency Mathias Greetiory Total Addressable Multiple Pathways to Market over $3B Commercialization